Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Harringtonolide is a bioactive diterpenoid tropone natural product isolated from the plant Cephalotaxus harringtonia. It possesses a unique cage-like polycyclic structure featuring a tropone ring, bridged lactone, and tetrahydrofuran ring. Harringtonolide exhibits potent antiproliferative and cytotoxic activity against various cancer cell lines (e.g., HCT-116, A375, A549, Huh-7), with reported IC50 values in the nanomolar range for some tumor cells. Its mechanism of action involves direct binding to receptor for activated C kinase 1 (RACK1), leading to inhibition of the epithelial–mesenchymal transition (EMT) process and suppression of cell proliferation by affecting the FAK/Src/STAT3 signaling pathway. These activities make it an effective antitumor agent candidate[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on harringtonolide.